Literature DB >> 7873196

Mucus glycoconjugate complexes released from feline trachea by a bacterial toxin.

D C Fung1, M Somerville, P S Richardson, J K Sheehan.   

Abstract

This paper describes low-density mucus glycoconjugates released from feline trachea by dirhamnolipid (DRL), a toxin from Pseudomonas aeruginosa. Mucus glycoconjugates in feline tracheas were radiolabeled in vivo with 3H-proline and 14C-glucose. Control mucus and that released by 200 micrograms/ml DRL were dissolved in guanidine hydrochloride buffer (GuHCl) and chromatographed on Sepharose CL-2B. Molecules eluting in the void volume (V0) of the column were isolated by isopycnic density gradient centrifugation in CsCl/GuHCl. All samples gave peaks of radiolabeled and periodic acid/Schiff (PAS)-reactive material at rho = approximately 1.50 and approximately 1.60 g/ml, but DRL-stimulated samples contained low-density material (rho < 1.32 g/ml), also PAS-reactive and radiolabeled. Control secretions incubated with DRL in vitro did not form low-density material. In Triton X-100 (1% vol/vol), a nonionic detergent, low-density material behaved as smaller molecules, running in the partially included volume (Vi) of the column of Sepharose CL-2B, but still in the V0 of Sephacryl S-300. Incubation with chondroitinase ABC, heparinase II and III, and keratanase failed to change its elution profile on S-300, evidence against glycosaminoglycans; but proteolysis with trypsin or proteinase K gave two peaks, peptide fragments near the totally included volume of the column and glycopeptides in V0. The V0 glycopeptides banded between 1.50 and 1.55 g/ml in a CsCl gradient and eluted as a single peak in the Vi of Sephacryl S-400, suggesting a distinct homogeneous glycopeptide, smaller than those from normal mucins. The main 14C-labeled sugars in this glycopeptide were fucose, glucosamine, galactosamine, and galactose, consistent with a mucin. Thus, DRL releases stable but noncovalent complexes containing one or more distinct mucinlike glycoconjugates, probably combined with lipids and peptides. We discuss their possible relevance to airway diseases, including cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7873196     DOI: 10.1165/ajrcmb.12.3.7873196

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  6 in total

1.  Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma.

Authors:  W R Henderson; E Y Chi; R K Albert; S J Chu; W J Lamm; Y Rochon; M Jonas; P E Christie; J M Harlan
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 2.  Rhamnolipids: diversity of structures, microbial origins and roles.

Authors:  Ahmad Mohammad Abdel-Mawgoud; François Lépine; Eric Déziel
Journal:  Appl Microbiol Biotechnol       Date:  2010-03-25       Impact factor: 4.813

3.  Surface translocation by Legionella pneumophila: a form of sliding motility that is dependent upon type II protein secretion.

Authors:  Catherine R Stewart; Ombeline Rossier; Nicholas P Cianciotto
Journal:  J Bacteriol       Date:  2008-12-29       Impact factor: 3.490

4.  The importance of leukotrienes in airway inflammation in a mouse model of asthma.

Authors:  W R Henderson; D B Lewis; R K Albert; Y Zhang; W J Lamm; G K Chiang; F Jones; P Eriksen; Y T Tien; M Jonas; E Y Chi
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

5.  Proteins Potentially Involved in Immune Evasion Strategies in Sporothrix brasiliensis Elucidated by Ultra-High-Resolution Mass Spectrometry.

Authors:  Luana Rossato; Leandro Ferreira Moreno; Azadeh Jamalian; Benjamin Stielow; Sandro Rogério de Almeida; Sybren de Hoog; Joanna Freeke
Journal:  mSphere       Date:  2018-06-13       Impact factor: 4.389

Review 6.  An Organ System-Based Synopsis of Pseudomonas aeruginosa Virulence.

Authors:  Charles D Morin; Eric Déziel; Jeff Gauthier; Roger C Levesque; Gee W Lau
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.